Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by quest13on Sep 04, 2013 12:18pm

157 Views

Post# 21717678

RE:Husk16 CC Recap Pt2

I listened to the phone conference call and unfortunately got called away just as the Q&A session started.
I am hoping that you have made notes of the Q&A as well and will put a recap of that part up since they eliminate the Q&A part on the webcast which is on the website.
I have always found the Q&A to be a very interesting part of these calls as unscripted answers often give tid-bits of information of interest.

Bullboard Posts

Unique Battery Metals opportunity in Quebec